Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers by Miguel Tregnaghi, Pio Lopez, Daniel Stamboulian, Gabriela Graña, Tatjana Odrljin, Lisa Bedell, Peter M. Dull

Get full text

The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of age. by Blanchard-Rohner, G, Snape, MD, Kelly, D, O'Connor, D, John, T, Clutterbuck, E, Ohene-Kena, B, Klinger, C, Odrljin, T, Pollard, A

The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age by Blanchard-Rohner, G, Snape, MD, Kelly, D, O'Connor, D, John, T, Clutterbuck, E, Ohene-Kena, B, Klinger, C, Odrljin, T, Pollard, A

Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults by Hoan Jong Lee, Moon-Hyun Chung, Woo Joo Kim, Young Jin Hong, Kyong Min Choi, Jina Lee, Chi Eun Oh, Jo Anne Welsch, Kyung-Hyo Kim, Ki Bae Hong, Alemnew F. Dagnew, Hans Bock, Peter M. Dull, Tatjana Odrljin

Get full text